Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.48 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.47 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.47 |
| ▸ | FAAH | O00519 | 2/20 | 0.45 |
| ▸ | PPARD | Q03181 | 6/20 | 0.45 |
| ▸ | PPARA | Q07869 | 6/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | ACR | P10323 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2430229 | 0.85 | TDP1 (0.39) | EPHX2NOTUMTRPV1FAAHPPARD | |
| SCHEMBL2983289 | 0.84 | NOTUM (0.64) | EPHX2NOTUMTRPV1FAAHPPARD | |
| SCHEMBL4437276 | 0.84 | EPHX2 (0.48) | EPHX2NOTUMTRPV1FAAHPPARD | |
| SCHEMBL2428467 | 0.83 | RAB9A (0.45) | EPHX2NOTUMTDP1L3MBTL1MAPT | |
| SCHEMBL2427499 | 0.81 | NOTUM (0.51) | NOTUMTDP1L3MBTL1MAPTHPGD | |
| SCHEMBL28946942 | 0.81 | SIRT2 (0.48) | EPHX2NOTUMTRPV1FAAHPPARD | |
| SCHEMBL31434746 | 0.80 | NOTUM (0.49) | NOTUMTDP1L3MBTL1MAPTHPGD | |
| SCHEMBL3968044 | 0.80 | NOTUM (0.72) | NOTUMTDP1L3MBTL1MAPTHPGD | |
| SCHEMBL1963850 | 0.78 | NOTUM (0.51) | NOTUMPPARDPPARATDP1L3MBTL1 | |
| SCHEMBL29241069 | 0.78 | NOTUM (0.51) | NOTUMTDP1L3MBTL1MAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE39916-E1 | Compounds that modulate PPAR activity and methods for their preparation | WARNER LAMBERT COMPANY (US) | 2007-11-06 | — | — | US | disclosed |
| US-RE39916-E1 | Compounds that modulate PPAR activity and methods for their preparation | WARNER LAMBERT COMPANY (US) | 2007-11-06 | — | — | US | disclosed |
| US-RE39916-E1 | Compounds that modulate PPAR activity and methods for their preparation | WARNER LAMBERT COMPANY (US) | 2007-11-06 | — | — | US | disclosed |
| US-7244763-B2 | Compounds that modulate PPAR activity and methods of preparation | WARNER LAMBERT COMPANY LLC (US) | 2007-07-17 | — | — | US | disclosed |
| US-7244763-B2 | Compounds that modulate PPAR activity and methods of preparation | WARNER LAMBERT COMPANY LLC (US) | 2007-07-17 | — | — | US | disclosed |
| US-7244763-B2 | Compounds that modulate PPAR activity and methods of preparation | WARNER LAMBERT COMPANY LLC (US) | 2007-07-17 | — | — | US | disclosed |
| US-20070054902-A1 | Isoxazole derivatives as peroxisome proliferator-activated receptors agonists | SHIONOGI & CO., LTD. (JP) | 2007-03-08 | — | — | US | disclosed |
| EP-1690538-A1 | ISOXAZOLE DERIVATIVE HAVING AGONISTIC ACTIVITY AGAINST PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR | SHIONOGI & CO., LTD. (JP) | 2006-08-16 | — | — | EP | disclosed |
| US-7056924-B2 | Substituted heterocyclic compounds | CV THERAPEUTICS, INC. (US) | 2006-06-06 | — | — | US | disclosed |
| US-7001909-B2 | Substituted heterocyclic compounds | CV THERAPEUTICS, INC. (US) | 2006-02-21 | — | — | US | disclosed |
| WO-2004091604-A1 | COMPOUNDS THAT MODULATE PPAR ACTIVITY AND METHODS OF PREPARATION | WARNER-LAMBERT COMPANY LLC (US) | 2004-10-28 | — | — | WO | disclosed |
| US-20040209936-A1 | Compounds that modulate PPAR activity and methods of preparation | BRATTON LARRY D (US) | 2004-10-21 | — | — | US | disclosed |
| CN-1533388-A | Substituted piperazine compounds and their use as fatty acid oxidation inhibitors | CVҽҩ����˾ | 2004-09-29 | — | — | CN | disclosed |
| US-20040176383-A1 | Substituted heterocyclic compounds | CV THERAPEUTICS, INC. | 2004-09-09 | — | — | US | disclosed |
| WO-2004067506-A2 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | CV THERAPEUTICS INC. (US) | 2004-08-12 | — | — | WO | disclosed |
| EP-1406898-A1 | SUBSTITUTED PIPERAZINE COMPOUNDS AND THEIR USE AS FATTY ACID OXIDATION INHIBITORS | CV THERAPEUTICS, INC. (US) | 2004-04-14 | — | — | EP | disclosed |
| US-20030225158-A1 | Compounds that modulate PPAR activity and methods for their preparation | WARNER-LAMBERT COMPANY | 2003-12-04 | — | — | US | disclosed |
| US-20030181352-A1 | Substituted heterocyclic compounds | CV THERAPEUTICS, INC. | 2003-09-25 | — | — | US | disclosed |
| US-20030176447-A1 | Substituted heterocyclic compounds | CV THERAPEUTICS, INC. | 2003-09-18 | — | — | US | disclosed |
| WO-2003008411-A1 | SUBSTITUTED PIPERAZINE COMPOUNDS AND THEIR USE AS FATTY ACID OXIDATION INHIBITORS | CV THERAPEUTICS, INC. (US) | 2003-01-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030181352-A1 | Substituted heterocyclic compounds | DLD, LPL, HDLBP | EPHX2 3188/4885NOTUM 725/4885TRPV1 548/4885 |
| US-20030176447-A1 | Substituted heterocyclic compounds | DLD, LPL, HDLBP | EPHX2 3188/4885NOTUM 725/4885TRPV1 548/4885 |
| US-20040176383-A1 | Substituted heterocyclic compounds | DLD, LPL, HDLBP | EPHX2 3188/4885NOTUM 725/4885TRPV1 548/4885 |
| US-20040209936-A1 | Compounds that modulate PPAR activity and methods of preparation | PPARA, PPARG, PPARD | EPHX2 2455/4885NOTUM 534/4885TRPV1 733/4885 |
| US-20030225158-A1 | Compounds that modulate PPAR activity and methods for their preparation | GPR119, PPARA, PPARG | EPHX2 3347/4885NOTUM 1370/4885TRPV1 365/4885 |
| US-20070054902-A1 | Isoxazole derivatives as peroxisome proliferator-activated receptors agonists | NR1H3, NR1H2, RXRA | EPHX2 3244/4885NOTUM 2840/4885TRPV1 2630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.